TriangleTMV Vaccine With Pembrolizumab (NCT06868433)
TMV Vaccine With Pembrolizumab trial for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06868433). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for head and neck squamous cell cancer that has come back or spread, in adults whose tumor can be treated with salvage surgery.
The idea: a vaccine made from the patient's own tumor. Tissue from surgery is used to make tumor membrane vesicles, given alone or together with pembrolizumab. Patients may have had up to three earlier regimens.
This phase 1 study looks for the safety and best dose of the vaccine, and plans 40 patients. At Emory University in Atlanta, Dong Shin leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.